Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00450385
Status:
TERMINATED
Last Update Posted:
2017-06-23
First Post:
2007-03-20
Brief Title:
Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy R-CHOP
Sponsor:
University of Miami
Organization:
University of Miami
Study Overview
Official Title:
Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP
Status:
TERMINATED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Investigator Decision due to insufficient accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
R-CHOP
Brief Summary:
The investigators hypothesize that survival of newly diagnosed DLBCL diffuse large B-cell lymphoma patients treated with R-CHOP can be predicted by RNA or protein gene expression or by presence of biomarkers associated with the anti-tumor effects of Rituximab
Detailed Description:
In this phase II multi-institutional trial the investigators will identify genes associated with either good or bad outcome in DLBCL patients treated with R-CHOP will construct a robust predictive models based on RNA extracted from or paraffin specimens as well on immunohistochemistry and will examine the predictive power of new biomarkers associated with the anti-tumor effects of rituximab The acquisition of fixed tissue as a component of this uniformly treated prospective study will also afford future studies with this informative dataset
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| WIRB-20070073 | OTHER | Western Institutional Review Board | None |
| SCCC-2006069 | OTHER | None | None |